<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0030085</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Perspective</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Genetics and Genomics</subject>
          <subject>Biochemistry/Drug Discovery</subject>
          <subject>Cardiovascular Disorders</subject>
          <subject>Infectious Diseases/HIV Infection and AIDS</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>HIV Infection/AIDS</subject>
          <subject>Drugs and adverse drug reactions</subject>
          <subject>Genetics</subject>
          <subject>Thrombosis and embolism</subject>
        </subj-group>
      </article-categories><title-group><article-title>Antiretroviral Therapy and Dyslipidaemia: Unlocking the Code</article-title><alt-title alt-title-type="running-head">Perspectives</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Mallon</surname>
            <given-names>Patrick W. G</given-names>
          </name>
        </contrib>
      </contrib-group><author-notes>
        <fn fn-type="current-aff" id="n1">
          <p>Patrick W. G. Mallon is at the National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, St. Vincent's Medical Centre, Sydney, Australia. E-mail: 
						<email xlink:type="simple">p.mallon@cfi.unsw.edu.au</email>
					</p>
        </fn>
      <fn fn-type="conflict" id="n2">
        <p>
						 PWGM has received honoraria (including advisory board honoraria), research grants, lecture fees, and/or travel grants from the following: Bristol-Myers Squibb, Merck Sharp and Dohme, GlaxoSmithKline, Gilead, Abbott, Roche, and Boehringer-Ingelheim.
					</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>3</month>
        <year>2006</year>
      </pub-date><pub-date pub-type="epub">
        <day>24</day>
        <month>1</month>
        <year>2006</year>
      </pub-date><volume>3</volume><issue>3</issue><elocation-id>e85</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2006</copyright-year><copyright-holder>Patrick W. G. Mallon</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article page="e52" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pmed.0030052" xlink:title="research article" xlink:type="simple">
				<article-title>Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1 Infected Individuals on Antiretroviral Therapy</article-title>
			</related-article><abstract abstract-type="toc">
        <p>Mallon discusses a new study that describes associations between apoC-III polymorphisms and triglyceride concentrations in a large population of HIV-infected patients from a variety of ethnic backgrounds.</p>
      </abstract></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>Dyslipidaemia, characterised by elevated total cholesterol, elevated non–high density lipoprotein (HDL) cholesterol, low HDL cholesterol, and elevated triglycerides, is common in patients with HIV who are treated with long-term antiretroviral therapy (ART) [<xref ref-type="bibr" rid="pmed-0030085-b1">1</xref>]. Although multiple factors influence lipid levels in patients treated with ART, exposure to protease inhibitors (PI) is thought to play an important role in the development of dyslipidaemia [<xref ref-type="bibr" rid="pmed-0030085-b2">2</xref>,
				<xref ref-type="bibr" rid="pmed-0030085-b3">3</xref>]. Data showing a relationship between length of exposure to ART and increased incidence of cardiovascular events [<xref ref-type="bibr" rid="pmed-0030085-b4">4</xref>] have heightened concern that ART-associated dyslipidaemia will result in increased rates of cardiovascular disease among ART-treated patients with HIV.
			</p>
      <p>The pathogenesis underlying ART-associated dyslipidaemia is thought to be related to drug-induced effects at the subcellular or molecular level [<xref ref-type="bibr" rid="pmed-0030085-b5">5–7</xref>]. This pathogenic mechanism, together with the interindividual variability in the prevalence and severity of ART-associated dyslipidaemia, suggests an important role for genetic factors in the pathogenesis of this dyslipidaemia. Small variations in genetic sequence, or single-nucleotide polymorphisms (SNPs), are common in the human genome [<xref ref-type="bibr" rid="pmed-0030085-b8">8</xref>]; many adverse drug reactions occur in response to drugs that are metabolised by enzymes known to contain functionally relevant polymorphisms [<xref ref-type="bibr" rid="pmed-0030085-b9">9</xref>]. Determining the effect of SNPs or groups of SNPs (halotypes) on an individual's response to either drugs or disease may help to limit these adverse drug reactions. This area has become a focal point of translational molecular research.
			</p>
    </sec>
    <sec id="s2">
      <title>Triglycerides and ApoC-III</title>
      <p>Apolipoproteins (apo) are important components of circulating lipoproteins. ApoC-III, a 79–amino acid glycoprotein synthesised in the liver and small intestine, is a major constituent of chylomicrons and very low density lipoproteins (VLDLs), both of which are triglyceride-rich lipoproteins. ApoC-III regulates the synthesis and catabolism of VLDL, an important contributor to plasma triglyceride concentrations [<xref ref-type="bibr" rid="pmed-0030085-b10">10</xref>]. In human studies, levels of apoC-III showed a positive correlation with plasma triglycerides, and higher apoC-III concentrations have been associated with recurrent cardiovascular events [<xref ref-type="bibr" rid="pmed-0030085-b11">11</xref>]. In studies of people with HIV, apoC-III levels showed a positive correlation with triglyceride concentrations in males with HIV [<xref ref-type="bibr" rid="pmed-0030085-b12">12</xref>], and apoC-III levels in males treated with PI were two to three times higher than controls [<xref ref-type="bibr" rid="pmed-0030085-b13">13</xref>].
			</p>
    </sec>
    <sec id="s3">
      <title>Influence of Polymorphisms on ApoC-III Function</title>
      <p>Regulation of apoC-III occurs at the level of its transcription. Insulin interacts with an insulin-responsive element in the promoter region of apoC-III, resulting in down regulation of apoC-III expression [<xref ref-type="bibr" rid="pmed-0030085-b10">10</xref>]. Within the insulin-responsive element, the presence of two apoC-III polymorphisms, -455T/C and -482C/T, affects the ability of insulin to down-regulate apoC-III expression in vitro [<xref ref-type="bibr" rid="pmed-0030085-b14">14</xref>]. These polymorphisms are common in populations infected with HIV [<xref ref-type="bibr" rid="pmed-0030085-b15">15</xref>,
				<xref ref-type="bibr" rid="pmed-0030085-b16">16</xref>]. Along with another polymorphism in the 3′ untranslated region termed SstI (3238C/G), these polymorphisms have been associated with hypertriglyceridaemia in studies of both HIV-positive and -negative populations [<xref ref-type="bibr" rid="pmed-0030085-b10">10</xref>,
				<xref ref-type="bibr" rid="pmed-0030085-b14">14–17</xref>].
			</p>
      <p>Two previous studies in patients with HIV explored the relevance of apoC-III polymorphisms to ART-associated dyslipidaemia. In one study, 60% of individuals expressing all three apoC-III variants together with an apoE variant experienced extreme hypertriglyceridaemia (greater than 7 mmol/l) when exposed to ritonavir, values more than two times those of patients with similar genetic profiles not on ART treatment [<xref ref-type="bibr" rid="pmed-0030085-b16">16</xref>]. In another study, patients receiving PI who carried the -482T or -455C alleles had higher triglycerides (50%–60% higher) than patients with wild-type apoC-III [<xref ref-type="bibr" rid="pmed-0030085-b15">15</xref>].
			</p>
      <p>Both studies had limitations. In the smaller study, the 60 patients were all White men prescribed PI-containing ART [<xref ref-type="bibr" rid="pmed-0030085-b15">15</xref>], and patients with pre-therapy dyslipidaemia were excluded. Only 21% of the data points studied were in patients taking ritonavir, a PI associated with dyslipidaemia [<xref ref-type="bibr" rid="pmed-0030085-b3">3</xref>] that is now increasingly used in small doses to pharmacologically “boost” the levels of other PIs. Although the larger study (
				<italic>n</italic> = 329) included women (21%), the cohorts were still predominantly White (88%) [<xref ref-type="bibr" rid="pmed-0030085-b16">16</xref>]. As there are large racial/ethnic differences in the prevalence of not only HIV [<xref ref-type="bibr" rid="pmed-0030085-b18">18</xref>] but also metabolic syndrome and dyslipidaemia [<xref ref-type="bibr" rid="pmed-0030085-b19">19</xref>], it is also important to determine the different effects of potentially functional polymorphisms across racial/ethnic groups if pharmacogenetic and genomic knowledge is to be applied to the treatment of diverse populations. These studies were not designed to address these issues.
			</p>
    </sec>
    <sec id="s4">
      <title>A New Study in a Racially/ Ethnically Diverse Population</title>
      <p>In the current issue of 
				<italic>PLoS Medicine</italic>, Foulkes et al. describe associations between apoC-III polymorphisms and triglyceride concentrations in a large (
				<italic>n</italic> = 626) population of patients with HIV from a variety of racial/ethnic backgrounds [<xref ref-type="bibr" rid="pmed-0030085-b20">20</xref>]. A strength of this study was that it derived samples and collected data through the Adult AIDS Clinical Trial Group (
				AACTG) A5128 Protocol, which allows for storage of DNA for pharmacogenetic and genomic research from participants enrolled in a range of 
				AACTG clinical trials [<xref ref-type="bibr" rid="pmed-0030085-b21">21</xref>]. In contrast to other studies, 19.3% of the population was Black/ non-Hispanic and 17.9% was Hispanic, allowing for investigations into the effect of the apoC-III polymorphisms both within and between different racial/ethnic populations.
			</p>
      <p>Foulkes et al. found wide variability in genotype frequency among different racial/ethnic groups with wild type less common among Black/non-Hispanics (10.8%) than among White/non-Hispanics (45.5%) and Hispanics (35.1%). The pattern and severity of dyslipidaemia also differed between groups. Although the Black/non-Hispanic group had lower triglycerides, lower non-HDL cholesterol, and higher HDL cholesterol levels than White/non-Hispanics and Hispanics, they experienced more pronounced increases in triglycerides in response to PI-containing ART.</p>
      <p>In contrast to previous literature, presence of variant apoC-III alleles in the Hispanic group was associated with a seemingly protective effect when exposed to PIs, as patients carrying these variant alleles had lower triglyceride values in response to PIs than those carrying wild type. Although seemingly counterintuitive, similar protective effects of variant allele combinations have been previously described in people who are HIV-negative [<xref ref-type="bibr" rid="pmed-0030085-b17">17</xref>], even though an underlying mechanism has yet to be determined. These data point to specific differences between racial/ethnic groups, not only in the prevalence of apoC-III polymorphisms, but also in the influence of these polymorphisms on PI-related hypertriglyceridaemia.
			</p>
      <p>This study does have some limitations. For example, women were underrepresented (11% compared to the 25% of North American people living with HIV who are women [<xref ref-type="bibr" rid="pmed-0030085-b18">18</xref>]); only 10% of patients on PI therapy were on ritonavir; and, as the authors acknowledge, the study still lacked the power to detect small interaction effects within different racial/ethnic groups. Nevertheless, this study demonstrates specific differences between racial/ethnic groups in both the occurrence of dyslipidaemia on ART and the influence of genetic factors on the prevalence of PI-related lipid abnormalities.
			</p>
    </sec>
    <sec id="s5">
      <title>Pharmacogenetics and Antiretroviral Therapy</title>
      <p>The study by Foulkes et al. is among an increasing number of pharmacogenetic studies in HIV. Genetic variation has been linked to the metabolism of antiretroviral drugs [<xref ref-type="bibr" rid="pmed-0030085-b22">22–24</xref>], drug hypersensitivity [<xref ref-type="bibr" rid="pmed-0030085-b25">25</xref>], and components of HIV-associated lipodystrophy [<xref ref-type="bibr" rid="pmed-0030085-b26">26–29</xref>] (<xref ref-type="table" rid="pmed-0030085-t001">Table 1</xref>), although several of these studies were small, enrolled predominantly non-Hispanic/White men, and studied polymorphisms that occur infrequently within populations. As a result, conflicting associations have been found [<xref ref-type="bibr" rid="pmed-0030085-b16">16</xref>,
				<xref ref-type="bibr" rid="pmed-0030085-b26">26–29</xref>], and the clinical applicability of results is unclear.
			</p>
      <table-wrap id="pmed-0030085-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0030085.t001</object-id><label>Table 1</label><caption>
          <title>Pharmacogenetic/Genomic Studies in HIV</title>
        </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0030085.t001" xlink:type="simple"/><!-- <table><thead><tr><td><bold>Study</bold></td><td><bold>Gene(s)</bold></td><td><bold>Polymorphism(s)/Alleles</bold></td><td><bold><italic>n</italic></bold></td><td><bold>Percent Male</bold></td><td><bold>Region</bold></td><td><bold>Race/Ethnicity</bold></td><td><bold>Summary of Findings</bold></td></tr></thead><tbody><tr><td>Fauvel et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b15">15</xref>&rsqb;</td><td><italic>APOC3</italic></td><td>455T/C, 482C/T, SstI</td><td>60</td><td>100&percnt;</td><td>Europe</td><td>Not studied</td><td>All three polymorphisms positively associated with triglyceride concentrations.</td></tr><tr><td>Tarr et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b16">16</xref>&rsqb;</td><td><italic>APOC3 APOE</italic></td><td>455T/C, 482C/T, SstI; &epsi;2, &epsi;4 alleles</td><td>329</td><td>79.3&percnt;</td><td>Europe</td><td>88&percnt; White, 7&percnt; Black, 3&percnt; Hispanic</td><td>High triglycerides with ritonavir treatment in individuals with <italic>APOC3</italic> and <italic>APOE</italic> variants.</td></tr><tr><td>Nolan et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b28">28</xref>&rsqb;</td><td><italic>TNF</italic>&alpha;</td><td>238G/A</td><td>191</td><td>100&percnt;</td><td>Australasia</td><td>100&percnt; White</td><td>Increased risk of progression to lipodystrophy in heterozygotes.</td></tr><tr><td>Maher et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b29">29</xref>&rsqb;</td><td><italic>TNF</italic>&alpha;</td><td>238G/A</td><td>96</td><td>89&percnt;</td><td>Europe</td><td>100&percnt; White</td><td>Higher frequency of 238G/A polymorphism in patients with lipodystrophy.</td></tr><tr><td>Tarr et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b16">16</xref>&rsqb;</td><td><italic>TNF</italic>&alpha;</td><td>238G/A</td><td>329</td><td>79.3&percnt;</td><td>Europe</td><td>88&percnt; White, 7&percnt; Black, 3&percnt; Hispanic</td><td>No effect of <italic>TNF</italic>a polymorphism on development of lipoatrophy.</td></tr><tr><td>Fellay et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b23">23</xref>&rsqb;</td><td><italic>MDR1 CYP2D6</italic></td><td>3435C/T; *3, *4, *6 alleles</td><td>123</td><td>Not studied</td><td>Europe</td><td>100&percnt; White</td><td>Lower plasma antiretroviral concentrations with 3435C/T polymorphism. Higher plasma antiretroviral concentrations with variant 2D6 allele.</td></tr><tr><td>Rotger et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b24">24</xref>&rsqb;</td><td><italic>CYP2B6</italic></td><td>516G/T</td><td>226</td><td/><td>Europe</td><td/><td>Greater NNRTI plasma concentrations in patients with 516T/T.</td></tr><tr><td>Haas et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b22">22</xref>&rsqb;</td><td><italic>CYP2B6</italic></td><td>516G/T</td><td>154</td><td>82&percnt;</td><td>North America</td><td>57&percnt; White, 32&percnt; Black, 10&percnt; Hispanic</td><td>Higher efavirenz levels and more early central nervous system side effects in individuals with 516G/T polymorphism.</td></tr><tr><td>Yang et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b27">27</xref>&rsqb;</td><td><italic>SREBP1</italic></td><td>322C/G</td><td>355</td><td>80&percnt;</td><td>International</td><td>57&percnt; White, 25&percnt; Black, 13&percnt; Hispanic</td><td>Presence of polymorphism not predictive of hyperlipidaemia.</td></tr><tr><td>Miserez et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b26">26</xref>&rsqb;</td><td><italic>SREBP1</italic></td><td>322C/G</td><td>71</td><td>Not studied</td><td>Europe</td><td>Not studied</td><td>Less antiretroviral-associated increase in total cholesterol in patients with 322G/G.</td></tr><tr><td>Mallal et al. &lsqb;<xref ref-type="bibr" rid="pmed-0030085-b25">25</xref>&rsqb;</td><td><italic>HLA-B</italic></td><td>HLA-B*5701</td><td>185</td><td>87&percnt;</td><td>Australasia</td><td>89&percnt; White</td><td>Association between HLA-B*5701 and hypersensitivity to abacavir.</td></tr></tbody></table> --></table-wrap>
      <p>Notable exceptions include a study showing a high incidence of hypersensitivity to the nucleoside reverse transcriptase inhibitor abacavir in patients with the HLA-B*5701 halotype [<xref ref-type="bibr" rid="pmed-0030085-b25">25</xref>], and another study that demonstrated significant racial/ ethnic differences in the frequency of polymorphisms in the gene-encoding cytochrome P450 2B6, which is responsible for metabolism of the non-nucleoside reverse transcriptase inhibitor efavirenz. The differences in the frequency of these polymorphisms help explain the observed differences in metabolism of this drug between different racial/ethnic groups [<xref ref-type="bibr" rid="pmed-0030085-b22">22</xref>]. The latter study was also performed as part of the 
				AACTG collaboration.
			</p>
    </sec>
    <sec id="s6">
      <title>Future Directions</title>
      <p>Of the 43 million people estimated to be currently living with HIV, 43% are women, 64% live in sub-Saharan Africa, 18% live in South and Southeast Asia, and 4.5% live in Latin America [<xref ref-type="bibr" rid="pmed-0030085-b18">18</xref>]. Although we still have much to learn about the importance of race and ethnicity in the long-term treatment of HIV, studies such as that by Foulkes et al. underscore the importance of both race/ethnicity and genetic factors in the long-term treatment of HIV.
			</p>
      <p>The study by Foulkes et al. underscores the importance of designing appropriately powered pharmacogenetic studies that include individuals from a wide variety of racial/ethnic backgrounds in order to determine the clinical importance of genetic variation. Although DNA banks raise ethical challenges [<xref ref-type="bibr" rid="pmed-0030085-b30">30</xref>], collaborations such as the 
				AACTG are an ideal framework in which to perform these studies. Establishing and supporting similar collaborative groups in other regions of the world is essential if further useful studies are to be performed in this field. Such studies are vital if the eventual goal of safe long-term therapy for HIV is to be realised worldwide.
			</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>PWGM is supported by funds from the National Heart, Lung, and Blood Institutes of the National Institutes of Health, grant number RO1 HL65953. The National Centre in HIV Epidemiology and Clinical Research is funded by the Commonwealth Department of Health and Ageing.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0030085-b1">
        <label>1</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Grinspoon</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Carr</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular risk and body-fat abnormalities in HIV-infected adults.</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <fpage>48</fpage>
          <lpage>62</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b2">
        <label>2</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Carr</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Samaras</surname>
              <given-names>K</given-names>
            </name>
            <name name-style="western">
              <surname>Burton</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Law</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Freund</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.</article-title>
          <source>AIDS</source>
          <year>1998</year>
          <volume>12</volume>
          <fpage>F51</fpage>
          <lpage>F58</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b3">
        <label>3</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Purnell</surname>
              <given-names>JQ</given-names>
            </name>
            <name name-style="western">
              <surname>Zambon</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Knopp</surname>
              <given-names>RH</given-names>
            </name>
            <name name-style="western">
              <surname>Pizzuti</surname>
              <given-names>DJ</given-names>
            </name>
            <name name-style="western">
              <surname>Achari</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.</article-title>
          <source>AIDS</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>51</fpage>
          <lpage>57</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b4">
        <label>4</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Friis-Moller</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Sabin</surname>
              <given-names>CA</given-names>
            </name>
            <name name-style="western">
              <surname>Weber</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>d'Arminio Monforte</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>El-Sadr</surname>
              <given-names>WM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combination antiretroviral therapy and the risk of myocardial infarction.</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>349</volume>
          <fpage>1993</fpage>
          <lpage>2003</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b5">
        <label>5</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Mallon</surname>
              <given-names>PW</given-names>
            </name>
            <name name-style="western">
              <surname>Unemori</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Sedwell</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Morey</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Rafferty</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.</article-title>
          <source>J Infect Dis</source>
          <year>2005</year>
          <volume>191</volume>
          <fpage>1686</fpage>
          <lpage>1696</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b6">
        <label>6</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Caron</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Auclair</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Vigouroux</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Glorian</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Forest</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.</article-title>
          <source>Diabetes</source>
          <year>2001</year>
          <volume>50</volume>
          <fpage>1378</fpage>
          <lpage>1388</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b7">
        <label>7</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Liang</surname>
              <given-names>JS</given-names>
            </name>
            <name name-style="western">
              <surname>Distler</surname>
              <given-names>O</given-names>
            </name>
            <name name-style="western">
              <surname>Cooper</surname>
              <given-names>DA</given-names>
            </name>
            <name name-style="western">
              <surname>Jamil</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Deckelbaum</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia.</article-title>
          <source>Nat Med</source>
          <year>2001</year>
          <volume>7</volume>
          <fpage>1327</fpage>
          <lpage>1331</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b8">
        <label>8</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sachidanandam</surname>
              <given-names>R</given-names>
            </name>
            <name name-style="western">
              <surname>Weissman</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Schmidt</surname>
              <given-names>SC</given-names>
            </name>
            <name name-style="western">
              <surname>Kakol</surname>
              <given-names>JM</given-names>
            </name>
            <name name-style="western">
              <surname>Stein</surname>
              <given-names>LD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms.</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>409</volume>
          <fpage>928</fpage>
          <lpage>933</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b9">
        <label>9</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Phillips</surname>
              <given-names>KA</given-names>
            </name>
            <name name-style="western">
              <surname>Veenstra</surname>
              <given-names>DL</given-names>
            </name>
            <name name-style="western">
              <surname>Oren</surname>
              <given-names>E</given-names>
            </name>
            <name name-style="western">
              <surname>Lee</surname>
              <given-names>JK</given-names>
            </name>
            <name name-style="western">
              <surname>Sadee</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review.</article-title>
          <source>JAMA</source>
          <year>2001</year>
          <volume>286</volume>
          <fpage>2270</fpage>
          <lpage>2279</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b10">
        <label>10</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Lai</surname>
              <given-names>CQ</given-names>
            </name>
            <name name-style="western">
              <surname>Parnell</surname>
              <given-names>LD</given-names>
            </name>
            <name name-style="western">
              <surname>Ordovas</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk.</article-title>
          <source>Curr Opin Lipidol</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>153</fpage>
          <lpage>166</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b11">
        <label>11</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Sacks</surname>
              <given-names>FM</given-names>
            </name>
            <name name-style="western">
              <surname>Alaupovic</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Moye</surname>
              <given-names>LA</given-names>
            </name>
            <name name-style="western">
              <surname>Cole</surname>
              <given-names>TG</given-names>
            </name>
            <name name-style="western">
              <surname>Sussex</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.</article-title>
          <source>Circulation</source>
          <year>2000</year>
          <volume>102</volume>
          <fpage>1886</fpage>
          <lpage>1892</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b12">
        <label>12</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Rimland</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Guest</surname>
              <given-names>JL</given-names>
            </name>
            <name name-style="western">
              <surname>Hernandez</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Del Rio</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Le</surname>
              <given-names>NA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.</article-title>
          <source>HIV Med</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>326</fpage>
          <lpage>333</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b13">
        <label>13</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Bonnet</surname>
              <given-names>E</given-names>
            </name>
            <name name-style="western">
              <surname>Ruidavets</surname>
              <given-names>JB</given-names>
            </name>
            <name name-style="western">
              <surname>Tuech</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Ferrieres</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Collet</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy.</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2001</year>
          <volume>86</volume>
          <fpage>296</fpage>
          <lpage>302</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b14">
        <label>14</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Li</surname>
              <given-names>WW</given-names>
            </name>
            <name name-style="western">
              <surname>Dammerman</surname>
              <given-names>MM</given-names>
            </name>
            <name name-style="western">
              <surname>Smith</surname>
              <given-names>JD</given-names>
            </name>
            <name name-style="western">
              <surname>Metzger</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Breslow</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia.</article-title>
          <source>J Clin Invest</source>
          <year>1995</year>
          <volume>96</volume>
          <fpage>2601</fpage>
          <lpage>2605</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b15">
        <label>15</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Fauvel</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Bonnet</surname>
              <given-names>E</given-names>
            </name>
            <name name-style="western">
              <surname>Ruidavets</surname>
              <given-names>JB</given-names>
            </name>
            <name name-style="western">
              <surname>Ferrieres</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Toffoletti</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients.</article-title>
          <source>AIDS</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>2397</fpage>
          <lpage>2406</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b16">
        <label>16</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Tarr</surname>
              <given-names>PE</given-names>
            </name>
            <name name-style="western">
              <surname>Taffe</surname>
              <given-names>P</given-names>
            </name>
            <name name-style="western">
              <surname>Bleiber</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Furrer</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Rotger</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.</article-title>
          <source>J Infect Dis</source>
          <year>2005</year>
          <volume>191</volume>
          <fpage>1419</fpage>
          <lpage>1426</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b17">
        <label>17</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dammerman</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Sandkuijl</surname>
              <given-names>LA</given-names>
            </name>
            <name name-style="western">
              <surname>Halaas</surname>
              <given-names>JL</given-names>
            </name>
            <name name-style="western">
              <surname>Chung</surname>
              <given-names>W</given-names>
            </name>
            <name name-style="western">
              <surname>Breslow</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1993</year>
          <volume>90</volume>
          <fpage>4562</fpage>
          <lpage>4566</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b18">
        <label>18</label>
        <nlm-citation publication-type="book" xlink:type="simple">
          <collab xlink:type="simple">Joint United Nations Programme on HIV/AIDS NetLibrary World Health Organization</collab>
          <source>AIDS epidemic update December 2005</source>
          <year>2005</year>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>Joint United Nations Programme on HIV/AIDS</publisher-name>
          <page-count count="98"/>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b19">
        <label>19</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Ford</surname>
              <given-names>ES</given-names>
            </name>
            <name name-style="western">
              <surname>Giles</surname>
              <given-names>WH</given-names>
            </name>
            <name name-style="western">
              <surname>Dietz</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey.</article-title>
          <source>JAMA</source>
          <year>2002</year>
          <volume>287</volume>
          <fpage>356</fpage>
          <lpage>359</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b20">
        <label>20</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Foulkes</surname>
              <given-names>AS</given-names>
            </name>
            <name name-style="western">
              <surname>Wohl</surname>
              <given-names>DA</given-names>
            </name>
            <name name-style="western">
              <surname>Frank</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Puleo</surname>
              <given-names>E</given-names>
            </name>
            <name name-style="western">
              <surname>Restine</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Associations among race/ethnicity, apoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.</article-title>
          <source>PLoS Med</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>e52</fpage>
          <comment>doi: <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030052" xlink:type="simple">10.1371/journal.pmed.0030052</ext-link></comment>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b21">
        <label>21</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Haas</surname>
              <given-names>DW</given-names>
            </name>
            <name name-style="western">
              <surname>Wilkinson</surname>
              <given-names>GR</given-names>
            </name>
            <name name-style="western">
              <surname>Kuritzkes</surname>
              <given-names>DR</given-names>
            </name>
            <name name-style="western">
              <surname>Richman</surname>
              <given-names>DD</given-names>
            </name>
            <name name-style="western">
              <surname>Nicotera</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: 
						AACTG Protocol A5128.</article-title>
          <source>HIV Clin Trials</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>287</fpage>
          <lpage>300</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b22">
        <label>22</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Haas</surname>
              <given-names>DW</given-names>
            </name>
            <name name-style="western">
              <surname>Ribaudo</surname>
              <given-names>HJ</given-names>
            </name>
            <name name-style="western">
              <surname>Kim</surname>
              <given-names>RB</given-names>
            </name>
            <name name-style="western">
              <surname>Tierney</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Wilkinson</surname>
              <given-names>GR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study.</article-title>
          <source>AIDS</source>
          <year>2004</year>
          <volume>18</volume>
          <fpage>2391</fpage>
          <lpage>2400</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b23">
        <label>23</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Fellay</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Marzolini</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Meaden</surname>
              <given-names>ER</given-names>
            </name>
            <name name-style="western">
              <surname>Back</surname>
              <given-names>DJ</given-names>
            </name>
            <name name-style="western">
              <surname>Buclin</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study.</article-title>
          <source>Lancet</source>
          <year>2002</year>
          <volume>359</volume>
          <fpage>30</fpage>
          <lpage>36</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b24">
        <label>24</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Rotger</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Colombo</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Furrer</surname>
              <given-names>H</given-names>
            </name>
            <name name-style="western">
              <surname>Bleiber</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Buclin</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.</article-title>
          <source>Pharmacogenet Genomics</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>1</fpage>
          <lpage>5</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b25">
        <label>25</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Mallal</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Nolan</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Witt</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Masel</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Martin</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.</article-title>
          <source>Lancet</source>
          <year>2002</year>
          <volume>359</volume>
          <fpage>727</fpage>
          <lpage>732</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b26">
        <label>26</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Miserez</surname>
              <given-names>AR</given-names>
            </name>
            <name name-style="western">
              <surname>Muller</surname>
              <given-names>PY</given-names>
            </name>
            <name name-style="western">
              <surname>Barella</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Schwietert</surname>
              <given-names>M</given-names>
            </name>
            <name name-style="western">
              <surname>Erb</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia.</article-title>
          <source>AIDS</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>2045</fpage>
          <lpage>2049</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b27">
        <label>27</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Yang</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>King</surname>
              <given-names>MS</given-names>
            </name>
            <name name-style="western">
              <surname>Han</surname>
              <given-names>L</given-names>
            </name>
            <name name-style="western">
              <surname>Isaacson</surname>
              <given-names>JD</given-names>
            </name>
            <name name-style="western">
              <surname>Mueller</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy.</article-title>
          <source>AIDS</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>2142</fpage>
          <lpage>2143</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b28">
        <label>28</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Nolan</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Moore</surname>
              <given-names>C</given-names>
            </name>
            <name name-style="western">
              <surname>Castley</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Sayer</surname>
              <given-names>D</given-names>
            </name>
            <name name-style="western">
              <surname>Mamotte</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy.</article-title>
          <source>AIDS</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>121</fpage>
          <lpage>123</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b29">
        <label>29</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Maher</surname>
              <given-names>B</given-names>
            </name>
            <name name-style="western">
              <surname>Alfirevic</surname>
              <given-names>A</given-names>
            </name>
            <name name-style="western">
              <surname>Vilar</surname>
              <given-names>FJ</given-names>
            </name>
            <name name-style="western">
              <surname>Wilkins</surname>
              <given-names>EG</given-names>
            </name>
            <name name-style="western">
              <surname>Park</surname>
              <given-names>BK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy.</article-title>
          <source>AIDS</source>
          <year>2002</year>
          <volume>16</volume>
          <fpage>2013</fpage>
          <lpage>2018</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030085-b30">
        <label>30</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>de Montgolfier</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Moutel</surname>
              <given-names>G</given-names>
            </name>
            <name name-style="western">
              <surname>Duchange</surname>
              <given-names>N</given-names>
            </name>
            <name name-style="western">
              <surname>Theodorou</surname>
              <given-names>I</given-names>
            </name>
            <name name-style="western">
              <surname>Herve</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients.</article-title>
          <source>Pharmacogenetics</source>
          <year>2002</year>
          <volume>12</volume>
          <fpage>667</fpage>
          <lpage>675</lpage>
        </nlm-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>
						AACTG
					</term>
          <def>
            <p>Adult AIDS Clinical Trial Group</p>
          </def>
        </def-item>
        <def-item>
          <term>apo</term>
          <def>
            <p>apolipoprotein</p>
          </def>
        </def-item>
        <def-item>
          <term>ART</term>
          <def>
            <p>antiretroviral therapy</p>
          </def>
        </def-item>
        <def-item>
          <term>HDL</term>
          <def>
            <p>high density lipoprotein</p>
          </def>
        </def-item>
        <def-item>
          <term>PI</term>
          <def>
            <p>protease inhibitor</p>
          </def>
        </def-item>
        <def-item>
          <term>SNP</term>
          <def>
            <p>single-nucleotide polymorphism</p>
          </def>
        </def-item>
        <def-item>
          <term>VLDL</term>
          <def>
            <p>very low density lipoprotein</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    
  </back>
</article>